Genmab scraps development of experimental cancer therapy
Dec 29, 2025, 9:16 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The cessation of late-stage trials indicates significant setbacks in product pipeline, historically correlating with declines in biotech stocks (e.g., Incyte's stock drop after halting a promising drug in late-stage trials).
AI summary
What happened, with direct paths to the underlying reporting
Genmab halts late-stage trials for its cancer antibody therapy. This decision may impact investor confidence and stock performance.
Genmab halts late-stage trials for its cancer antibody therapy.
This decision may impact investor confidence and stock performance.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Genmab’s stock rallied on three October Phase 3 wins, led by petosemtamab with Keytruda. The company is moving to own more of its medicines, funding acquisitions with debt, and ex…
Genmab reported positive LiGeR-HN1 topline results for petosemtamab with Keytruda, showing a 50% reduction in death risk versus pembrolizumab alone in first-line PD-L1+ recurrent/…
Genmab reported updated Phase 2 results for petosemtamab with pembrolizumab in first-line PD-L1+ r/m HNSCC, delivering a median OS of 28.2 months and an ORR of 63% in 43 efficacy-…
Genmab's Phase 3 EPCORE DLBCL-1 trial results showed no significant overall survival benefit for epcoritamab against standard chemotherapy, raising concerns regarding its accelera…